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Abstract
Background: The symptoms of multiple sclerosis (MS) are caused by damage to myelin and nerve cells in the brain
and spinal cord. Inflammation is tightly linked with neurodegeneration, and it is the accumulation of neurodegeneration
that underlies increasing neurological disability in progressive MS. Determining pathological mechanisms at play in MS
grey matter is therefore a key to our understanding of disease progression.
Methods: We analysed complement expression and activation by immunocytochemistry and in situ hybridisation in
frozen or formalin-fixed paraffin-embedded post-mortem tissue blocks from 22 progressive MS cases and made
comparisons to inflammatory central nervous system disease and non-neurological disease controls.
Results: Expression of the transcript for C1qA was noted in neurons and the activation fragment and opsonin
C3b-labelled neurons and glia in the MS cortical and deep grey matter. The density of immunostained cells
positive for the classical complement pathway protein C1q and the alternative complement pathway activation
fragment Bb was significantly increased in cortical grey matter lesions in comparison to control grey matter. The
number of cells immunostained for the membrane attack complex was elevated in cortical lesions, indicating
complement activation to completion. The numbers of classical (C1-inhibitor) and alternative (factor H) pathway
regulator-positive cells were unchanged between MS and controls, whilst complement anaphylatoxin receptor-bearing
microglia in the MS cortex were found closely apposed to cortical neurons. Complement immunopositive neurons
displayed an altered nuclear morphology, indicative of cell stress/damage, supporting our finding of significant
neurodegeneration in cortical grey matter lesions.
Conclusions: Complement is activated in the MS cortical grey matter lesions in areas of elevated numbers of
complement receptor-positive microglia and suggests that complement over-activation may contribute to the
worsening pathology that underlies the irreversible progression of MS.
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Background
Multiple sclerosis (MS) is an inflammatory, demyelinat-
ing and neurodegenerative disease of young adults.
Damage can occur throughout the central nervous sys-
tem, and the pathology of the grey matter can be exten-
sive [1, 2]. Progressive MS, marked by increasing
irreversible disability and reduced quality of life, is char-
acterised pathologically by extensive cortical demyelin-
ation [3]. Magnetic resonance imaging has demonstrated
that an increasing number of cortical lesions, and lesions
of deep grey matter, are predictive of disease course [4].
Grey matter pathology is seen from the earliest stages, and
inflammation is linked to neurodegeneration throughout
the disease [5]. There are now concerted efforts to better
understand the innate and adaptive immune mechanisms
that drive this pathology to identify disease relevant prog-
nostic markers and new therapeutic opportunities.
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The complement system is central to innate and
adaptive immune responses. Complement is synthe-
sised in the brain, and adult human neurons are a
major source of parenchymal complement [6], which
can also be generated systemically. Complement is im-
portant for synaptic pruning during development,
complement signalling causes neuronal morphological
changes in the adult and complement-labelled neurons
are targeted by complement receptor-bearing phago-
cytes [7–10]. Complement is activated through the
classical, lectin and alternative pathways that generate
anaphylatoxins C3a and C5a and opsonins, including
C3b [11, 12]. Build-up of complement fragment C3b
can lead to C5 convertase formation with proteolysis
of the C5 component and subsequent activation of the
terminal pathway leading to the formation of the
membrane attack complex (MAC). To avoid self-
injury, host cells express an array of complement regu-
latory proteins (Cregs) that, for example, inhibit C3-
cleaving enzymes (factor H), prevent C1q assembly
with C1r, s and initiation of the classical pathway (C1-
inhibitor) or block assembly of the MAC (clusterin)
[13]. Intrathecal and blood-borne levels of comple-
ment proteins mirror the MS disease profile [14–17],
but we need to know more about the role of comple-
ment in pathogenesis.
Evidence for complement activation in MS grey mat-
ter is mixed, with some reporting little evidence for
complement activation in purely cortical lesions [18].
Others have shown complement to be differentially
expressed [19–21] and the complement recognition
and initiation protein C1q to be associated with degen-
erating synapses in the MS hippocampus [22]. As yet,
Creg expression in MS grey matter has not been re-
ported. We have examined the localisation of comple-
ment recognition molecules (C1q), activation products
(C3b, Bb, MAC), regulators (factor H, C1 inhibitor,
clusterin) and receptors (C3aR, C5aR and complement
receptor 3/ CD11b) for the first time in order to better
understand the immune mechanisms of MS cortical
grey matter pathology relevant to disease progression.
Methods
Study cohort
Tissue was provided by the UK Multiple Sclerosis Society
Tissue Bank (MSSTB) at Imperial College (MS and non-
neurological controls, including cryopreserved samples)
and the Oxford Brain Bank, Oxford University (inflamma-
tory and non-neurological controls) with appropriate re-
search ethics approval (South West Wales REC study
approval 13/WA/0292). Of these samples, 22 cases of neu-
ropathologically confirmed MS, 15 non-neurological con-
trols and eight non-MS neurological controls with glial
activation and neuroinflammation (four ischaemic stroke,
four viral encephalitis; referred to collectively as “non-MS
inflammatory controls”) were used for the main data col-
lection (Table 1 and Additional file 1:Table S1). Non-
neurological and non-MS inflammatory controls were
selected based on the availability of tissue blocks from the
pre-determined study regions and gender and age similar
to the available MS cohort. In all instances, the fresh brain
was cut into 1-cm-thick coronal slabs before either cryo-
preserving in cold isopentane on a bed of dry ice or placed
in freshly prepared fixative (for formalin-fixed, paraffin-
embedded samples). Sections from representative anatom-
ically matched brain regions were prepared for each case
as follows: (1) superior frontal gyrus, (2) cingulate gyrus,
(3) thalamus, and (4) hippocampus and inferior temporal
lobe. Cryosections from region-matched blocks of
frontal, cingulate and hippocampus and inferior tem-
poral lobe were available for the complete MS cohort
and, together with an additional eight non-neurological
controls (MSSTB), were used to assess complement ter-
minal pathway activation (staining for C9neo and clus-
terin) and complement receptor staining.
Tissue characterisation
All cases were processed histologically for luxol fast
blue/cresyl fast violet and haematoxylin/eosin, and sub-
sequent sections were stained with antibodies to myelin-
oligodendrocyte-glycoprotein (MOG) and human leukocyte
antigen (HLA-D) to determine tissue architecture, cellular
infiltration, demyelination and the density of microglia/
Table 1 Summary of multiple sclerosis and control groups used for quantitative analysis
Cohort Status (n) Gender Age at death Disease duration PMD
Multiple sclerosis 18 SPMS 9M:13F 50 years (38–66) 25 years (10–39) 17 h (9–26)
4 PPMS
Inflammatory Ctrls 4 viral encephalitis 6M:2F 37 years (17–65) n/a 36 h (24–72)
4 ischaemia
Non-neurological Ctrls 15 controls 9M:6F 67 years (35–88) n/a 24 h (5–48)
Inflammatory controls are non-MS neurological controls characterised by neuroinflammation and gliosis. Group values showed as median (data range). See
(Additional file 1: Table S1) for individual case details including cause of death, disease activity at death and sampled blocks
Ctrls controls, disease duration determined retrospectively from time of first symptom onset to death, F female, M male, PMD post-mortem delay, PPMS primary
progressive MS, SPMS secondary progressive MS, n/a not applicable
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macrophages (Figs. 1 and 2 and Additional file 1: Figure
S1). White matter lesions (WML), deep grey matter (thal-
amus) and hippocampus lesions of MS were classified as
follows: active (demyelinated lesion core confluent with
HLA-D+ microglia/macrophages and the presence of early
myelin (MOG+ inclusion) degradation products); chronic
active (HLA-D+ microglia/macrophages restricted to the
lesion edge and the presence of early and late (LFB+ inclu-
sion) myelin degradation products) or chronic inactive
(pale or no rim of ramified microglia (with late myelin deg-
radation products) at the edge). Grey matter lesions (GML)
of the frontal, cingulate and temporal gyri were charac-
terised based on location within the cortical laminae and
were described as subpial (type III), intracortical (type II)
and leukocortical involving the subcortical white matter
(type I) or as lesions spanning the entire width of cortex
from the pia to the leukocortical junction, but without in-
volving the white matter (type IV) [23]. Our analysis of le-
sions affecting the deep cortical laminae (layers V and VI)
included both type I and IV lesion areas. All cortical
GMLs used in this study (subpial and those affecting the
deep cortical laminae) were characterised as chronic (ac-
tive or inactive) based on the number and distribution of
HLA-D+ microglia/macrophages and the presence of
early (chronic active) or late (chronic inactive) myelin deg-
radation products [24].
Immunostaining protocols and image capturing
Paraffin wax sections were de-waxed, rehydrated and
subjected to heat-induced epitope retrieval as described
previously [25]. Following overnight incubation with the
primary antibody, sections were incubated with biotinyl-
ated secondary antibody and avidin-biotin peroxidase
complex with diaminobenzidine as the chromogen
(Impact DAB; Vector Laboratories Ltd., Peterborough,
Cambridgeshire, UK). Individual antibody details are
listed in Additional file 1: Table S2. Snap-frozen, unfixed
cryosections were air-dried, fixed in methanol or 4 %
paraformaldehyde and quenched with H2O2 before
immunostaining. Immunofluorescence staining was
performed on wax or snap-frozen sections by sequen-
tial antibody incubation and detection, followed by
diamidino-2-phenylindole (DAPI) counterstaining. In
all instances, sections from each MS case for each anti-
body were immunostained in the same experimental
run to ensure comparability of labelling. All experi-
ments included primary antibody-negative controls
and irrelevant species-specific antisera as positive con-
trols. Sections were viewed on a Leica DRMB bright-
field microscope (Leica Microsystems, Milton Keynes,
Buckinghamshire, UK), a Zeiss Axio Imager under epi-
fluorescence or a Zeiss LSM 710 confocal (Carl Zeiss
Ltd., Cambridge, Cambridgeshire, UK).
Quantitative analysis
All quantification and analysis was performed with the
researcher blinded to the case identity. The mean num-
ber of immunostained cells was calculated for each com-
plement protein or cell phenotypic marker of interest
from ×100 images (field of view (fov) area = 0.3 mm2) of
regions of interest: normal or demyelinated cortical lam-
inae I–III (i.e. subpial lesions); normal or demyelinated
cortical laminae V–VI (i.e. leukocortical and type IV le-
sions); normal or demyelinated subcortical white matter;
and for C3b-iC3b only, normal or lesioned thalamus
(ventral nucleus) and normal or lesioned CA1 of the ros-
tral hippocampus. Positively stained cells were manually
tagged in ImageJ (http://imagej.nih.gov/ij/) using the
“multipoint” tool. Layer V NeuN-immunopositive neurons
were automatically counted using the “analyse particles”
tool following image transformation and thresholding.
Changes in nuclear area and shape indicate cell stress/
damage [26, 27]. We investigated the nuclear morphology
of Smi32+ pyramidal neurons of layers V–VI co-labelled
with anti-C3b-iC3b using high-resolution confocal z-
stacks (captured under sequential scanning of the blue,
green and red channels, using a plan apochromat ×63/
1.40 oil immersion objective, image scaling = 0.07 μm/
pixel, optical section = 0.5 μm). Images of single (Smi32+,
C3b−)- or double (Smi32+/C3b+)-stained cells were
imported to ImageJ, and optical sections, where the nu-
cleus was sectioned most centrally (visible nucleolus and
z-section where nucleus at its widest diameter), were out-
lined using the “wand” tool and morphometric parameters
calculated for each nucleus using the “shape descriptors”
tool. A minimum of twenty co-labelled Smi32/C3b-iC3b+
neurons per case, from eight MS cases, were assessed.
In situ hybridisation
In situ hybridisation was performed according to the
method described by Budde et al. [28]. Sections previously
immunostained with anti-NeuN (Additional file 1: Table
S2) and detected with a goat anti-mouse-alkaline phosphat-
ase antibody (AP, Dako, Glostrup, Denmark), visualised
with Vector Blue AP substrate kit (Vector Laboratories).
The hybridisation was performed using a 5′ fluorescein
(FAM)-labelled 19mer antisense oligonucleotide that con-
tains locked nucleic acid (LNA) and 2′-O-methyl (2′-O-
Me)-RNA moieties (C1q: FAM-TggTccTugAugTuuCcuG,
capitals indicate LNA and lower case are 2′-O-Me RNA;
Ribo Task ApS, Odense, Denmark). Briefly, sections were
pre-hybridised in hybridisation mix (4 M urea in 600 mM
NaCl, 10 mM HEPES buffer, pH 7.5, 1 mM EDTA and ×5
Denhardt’s reagent) before probe hybridisation at 55 °C for
45 min in the same solution. Following hybridisation, sec-
tions were washed in saline-sodium citrate buffer, and the
probe was detected using a sheep anti-fluorescein-AP Fab
fragment (Roche Diagnostics GmbH, Penzberg, Germany)
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Fig. 1 Complement activation in MS grey matter lesions. Complement expression was investigated in cortical (a) and subcortical (b, c) grey
matter characterised by anti-myelin oligodendrocyte glycoprotein (MOG) and anti-HLA-D immunochemistry, to reveal demyelinated lesions (lesion
edge marked by arrows in a–c) and activated microglia, in the absence of amoeboid macrophages (d). Complement C1qA mRNA (red-brown reaction
product) was expressed in MS cortical grey matter neurons (NeuN+, blue; e), whilst complement activation fragment C3b-iC3b (hereafter referred to as
C3b+) was localised to the membrane and cytoplasm of neurons and glia (cell-associated immunolabelling noted by arrows, f). Quantitative analysis of
the density of C3b+ cells in cortical, deep grey matter and hippocampus from MS, non-MS inflammatory control and non-neurological controls (g).
C3b+ cell density was increased in cortical and deep grey matter lesions in comparison to area-matched non-neurological controls (g). The proportion
of C3b+ cells with a neuronal morphology was increased in MS cortex in comparison to non-neurological control (h). Anti-C3b immunolabelled myelin
closely associated with a HLA+ macrophage (i), oligodendrocytes (j) and microglia (k). Abbreviations: Ctrl non-neurological control cohort, IC non-MS
inflammatory controls, GMN grey matter normal, GML grey matter lesion. Each data point represents the mean value per area of interest (lesion,
normal-appearing or control) for the respective grey matter field, per case. Group means and 95 % confidence interval are plotted and compared by
Kruskal-Wallis and Dunn’s multiple comparison post-test. Scale bars: a–c, 2 mm; d–f, 50 μm; i–k, 5 μm
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Fig. 2 (See legend on next page.)
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and a rabbit anti-sheep immunoglobulin G/horseradish
peroxidase (HRP) (Dako). HRP was visualised using Vector
NovaRED (red-brown reaction product) prior to perman-
ent mounting (VectaMount, Vector Laboratories).
Data presentation and statistical testing
Data was handled in Excel (Microsoft Office, 2010) and
analysed using GraphPad Prism (v6.05, GraphPad Soft-
ware, CA, USA). Appropriate multi-group comparisons
and correlation analysis were performed following
D’Agostino and Pearson normality testing. In all in-
stances, case means per region of interest (e.g. GML,
WML) were compared and a p < 0.05 was regarded as
significant.
Results
Complement is activated in MS cortical and deep grey
matter
Chronic inflammatory demyelinating lesions of the neo-
cortex, thalamus and hippocampus grey matter (GM)
were identified by histological and immunohistochemical
assessment (Fig. 1a–d) as described in the methods. In
situ hybridisation for complement C1QA transcript
showed that complement C1q is synthesised by neurons
of the deep cortical laminae in MS (Fig. 1e). Neurons
and glia were immunostained with an antibody to the
central complement component C3b (and its initial
cleavage product iC3b) (Fig. 1f ). Quantification of C3b
immunopositive cells revealed an increased number in
MS GMLs (of cortical and deep grey matter—thalamus),
in comparison to non-neurological controls (Fig. 1g).
There was an increase in the proportion of C3b+ cells
with a neuronal morphology out of the total number of
C3b+ quantified cells in MS cortical GM (normal appear-
ing grey matter (GMN) and GML), in comparison to non-
neurological control samples (Fig. 1h). In addition to
notable labelling of cells resembling neurons (arrows in
Fig. 1f), C3b immunoreactive myelin was present, fre-
quently closely apposed with HLA-D+ phagocytes (Fig. 1i);
oligodendrocytes (Olig-1+; Fig. 1j) and microglia (Iba-1+;
Fig. 1k). The number of C3b immunostained cells was not
associated with confounding variables such as age of
death, post-mortem delay or whether death was infection
related (Additional file 1: Table S3).
Classical, alternative and terminal pathway activation
products are present in MS cortical grey matter lesions
We focussed our attention on describing complement ac-
tivation in association with neocortical demyelination and
neurodegeneration in progressive MS. Cortical GMLs
were described as subpial, leukocortical or spanning the
entire cortical ribbon but without affecting the underlying
white matter (Fig. 2a–d). The majority of cortical GMLs
were chronic inflammatory demyelinating lesions whilst
classically active cortical GMLs were infrequently ob-
served (Fig. 2e). In a classically active cortical GML (con-
fluent with HLA-D+ macrophages containing early myelin
degradation products; Fig. 2e′–e′′), complement C1q and
complement activation fragment C3b+ cells were noted
(Fig. 2e′′′). We stained and quantified the density of C1q,
fragment Bb and C9neo immunopositive cells in MS
normal-appearing GM and chronic GML areas, in
comparison to non-MS inflammatory controls and non-
neurological controls. Cells with a neuronal, oligodendro-
cyte and/or astrocyte-like morphology were labelled by
antibodies against C1q, fragment Bb and C9neo in grey
and white matter areas (Fig. 2f–h; (Additional file 1: Fig-
ures S2, S3)). The pattern of cell-associated complement
labelling in MS and control brain was similar to that seen
in Alzheimer’s disease cortex, which was used as a positive
staining control (see Additional file 1: Figure S4). Immu-
nostaining revealed a significantly greater number of
complement-labelled cells (neurons and glia) in deeper
cortical laminae of the MS GMLs (leukocortical and type
IV) in comparison to region and neuronal layer-matched
controls (Fig. 2i–k). The number of C1q+ and C3b+ cells
was elevated in active cortical GMLs (albeit with an n = 2)
in comparison to chronic cortical GMLs (n = 18; 12.0 and
31.1 positive cells per field of view compared with 7.7 ±
1.8 and 12.5 ± 2.6 C1q and C3b+ cells in active and
chronic GML groups, respectively). The density of C9neo
+ cells, determined from unfixed, cryopreserved samples
from the same cortical regions from the same MS cases,
was significantly elevated in deep cortical (leukocortical
and type IV) and subpial (type III) GMLs in comparison
(See figure on previous page.)
Fig. 2 Classical, alternative and terminal complement pathway activation in MS cortical lesions. Control (a) and MS cortex (b–d) immunostained
for MOG and HLA-D to reveal lesions affecting the deeper cortical laminae (b, c, arrows indicate lesion edge of a type I and type IV lesion, respectively)
and a subpial lesion (d). Within an active cortical grey matter lesion (e–e′′ arrows indicate lesion edge in e and e′ and early myelin degradation
products in e′′), C1q+ and C3b+ immunostaining was noted (arrows indicate labelled cells. Note the total absence of C3b immunolabelling
of a neuron directly adjacent to a C3b+ cell (e′′). Immunolabelling of cells morphologically resembling neurons and glia in the deep cortical
laminae of control and MS lesions indicated activation of the classical (C1q+, f, f′), alternative (fragment Bb+, g, g′) and terminal (C9neo+,
h, h′) complement pathways (arrows in insets in f′–h′ highlight immunopositive neurons or glia). The numerical density of C1q+ (i), fragment
Bb+ (j) and C9neo+ (k) cells was increased in grey matter and white matter lesions. Each data point represents the mean value per area of interest
per case and group means and 95 % confidence intervals plotted. Groups were compared by Kruskal-Wallis and Dunn’s multiple comparison
post-test. Scale bars: a–d, 2 mm; e–g, 100 μm
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to non-inflammatory controls. WMLs generally displayed
two- to tenfold more complement immunopositive cells
in comparison to grey matter areas in the same tissue
block. The density of C1q-, Bb- and C9neo-positive cells
in MS WMLs was increased in comparison to normal-
appearing and control white matter (Fig. 2i–k, Additional
file 1: Figure S3).
The expression of key complement classical, alternative
and terminal pathway regulators in cortical grey matter
lesions is similar in MS and controls
We next determined the numerical density of cells immu-
nolabelled for the classical pathway Creg, C1-inhibitor
(C1INH), the alternative pathway regulator factor H (FH)
and the terminal pathway regulator clusterin (Fig. 3). In
agreement with our description of complement activation
fragment staining, Creg staining was seen on and within
cells with a neuronal and/or glial morphology in cortical
grey matter areas (Fig. 3a–c, Additional file 1: Figures S2,
S3). The number of C1INH and FH immunolabelled cells
was unchanged between MS and control (Fig. 3d, e),
whilst the density of clusterin immunostained cells was
increased in MS GMN regions in comparison to non-
neurological controls (Fig. 3f, note that cryosections of in-
flammatory controls were not available). These data imply
that classical and alternative pathways are active despite
unchanged expression of key Cregs in lesions of the dee-
per cortical laminae.
Fig. 3 The expression of key regulators of the classical and alternative complement pathways are unchanged in MS cortical grey matter. Complement
C1-inhibitor+ (C1INH, classical pathway regulator), factor H+ (FH; alternative pathway regulator) and clusterin (Clu, terminal pathway regulator)
expression in and on cells of the cortical grey matter (a–c′; cells with a distinct neuronal morphology are shown in insets and arrows indicate
cytoplasm/membrane immunoreactivity). The number of C1INH+ (d) and FH+ (e) cells were unchanged in GMLs in comparison to controls.
There was an increase in the density of Clu+ cells (f ) in the GMN of the deep cortical laminae and in the GMN and GMLs of the subpia.
Each data point represents the mean value per area of interest and group means and 95 % confidence interval are shown. Groups compared with
Kruskal-Wallis and Dunn’s multiple comparison post-test. Scale bars: a–c, 100 μm
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Microglia are complement anaphylatoxin receptor
positive and are increased in density in cortical grey
matter lesions
We immunostained cryopreserved MS tissue from our
complete MS cohort to reveal the presence of com-
plement receptor 3+ (CR3/CD11b), C3aR+ and C5aR
+ cells with a microglial morphology in close contact
with cortical neurons (Fig. 4a–c). C5aR+ microglia
were activated (HLA-D+, Fig. 4d) and were signifi-
cantly increased in number in GMLs and WMLs, in
comparison to normal appearing tissues in the same
blocks from the same cases (Fig. 4e, f ). HLA-D+
microglia were seen tightly associated with C3b+ cor-
tical neurons and the density of activated microglia
(C5aR+ and HLA-D+ cells) correlated with the num-
ber of classical (C1q+) and alternative (fragment Bb+)
cells in GMLs affecting the deep cortical laminae
(Fig. 4h).
Complement is associated with morphological and
immunophenotypic markers of stress and
neurodegeneration in MS cortical grey matter lesions
C3b+ neurons of the deeper cortical laminae were iden-
tified by their co-expression of non-phosphorylated neu-
rofilament protein (Smi32+, Fig. 5a, b). Complement
activation fragment C3b immunostaining visualised by
confocal microscopy was noted on the surface and in
the cytoplasm of cortical neurons (Fig. 5a), whilst some
of these cells had an altered nuclear morphology
(Fig. 5b). The proportion of cortical neurons (Smi32+)
that were complement C3b+ was increased in MS GML
(Fig. 5c). C3b+ neurons in MS cortex showed signs of
nuclear stress as defined by morphometric analysis of
nuclear area and shape (aspect ratio; Fig. 5d, e) [27].
Quantitative evidence of neuronal dysmorphia was sup-
ported by the presence of C3b+ neurons expressing
hypo-phosphorylated neurofilaments (Smi34+), neuronal
Fig. 4 Microglial activation and complement anaphylatoxin receptor expression in the MS cortex. Expression of the opsonin receptor (CR3/CD11b)
and anaphylatoxin receptors C3aR and C5aR identified microglia (arrows in a–c) in the MS grey matter, some of which closely apposed neurons
(identified by Smi32 immunoreactivity or haematoxylin counterstain) in the demyelinated cortex (a–c). C5aR expression identified activated microglia
(d) and the density of HLA-D+ and C5aR+ microglia was elevated in MS cortical lesions in comparison to normal-appearing grey matter (e, f). Example
of an activated microglial cell associated with a C3b+ neuron (g). The number of HLA-D+ and C5aR+ cells were significantly correlated and
the number of C5aR+ cells associated with activation of the classical and alternative complement pathways (h). e, f, Bar graphs of group means ±
standard deviations; Mann-Whitney test. h, Spearman non-parametric comparison of the density of immunopositive cells in the demyelinated MS
cortex. Scale bars: a, b, 20 μm; c, d, g, 10 μm
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nuclei expressing the pro-apoptotic kinase and neur-
onal stress/damage marker protein kinase R (pPKR)
[29]—that were more numerous in MS GM in compari-
son to control GM (Fig. 5g, g′), and the presence of
C3b+/cleaved caspase3+ or C3b+/TUNEL reaction+
cortical neurons (Fig. 5h, i). Within the same regions of
interest, there was a significant reduction in the num-
ber of NeuN+ neurons in normal (p = 0.013) and
Fig. 5 Complement-associated neuronal damage and loss. Large pyramidal neurons (Smi32+) of the deeper laminae of the demyelinated MS cortex
displayed surface and cytoplasmic immunoreactive for C3b (a, arrows indicate surface-associated immunoreactivity visualised in a single 0.5-μm optical
section acquired by confocal microscopy), some of which (b, projected z-stack image) displayed a dysmorphic nucleus (arrow). Twice as many neurons
were immunolabelled with anti-C3b in the MS cortex in comparison to control tissues (c) and C3b+ neurons in MS (Smi32+) displayed a markedly
altered nuclear area and aspect ratio (d, e; Box and whiskers plot of median, interquartile and minimum to maximum data range). C3b+ neurons
expressed aberrant neurofilaments in the perikarya (f; hypo-phosphorylated neurofilaments, Smi34+) were positive for the pro-apoptotic kinase
phosphorylated PKR (g) and the numbers of pPKR+ neuronal nuclei were elevated in MS cortex (g′) in comparison to control. Complement-labelled
neurons occasionally expressed the apoptosis-associated markers (h) activated caspase3 (p17 subunit) and (i–i′′′) DNA strand breaks (TUNEL
reaction positive, C3b+ neuron). The density of NeuN+ neurons was reduced in normal appearing (18 % reduction) and lesioned (25 % reduction)
layer V grey matter, in comparison to non-neurological controls (j–j′′). Group medians compared by the non-parametric Mann-Whitney test (c–e)
or Kruskal-Wallis and Dunn’s multiple comparison post-test (j′′). Scale bars: a, b, 50 μm; f–i, 25 μm; j, j′, 200 μm
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lesioned cortical layer V MS GM (p = 0.002) in com-
parison to region matched non-neurological controls
(Fig. 5j–j′′).
Discussion
Progressive MS is associated with a widespread and
chronic activation of the central immune response con-
fined behind a relatively intact blood-brain barrier [2,
30]. Our quantitative analysis demonstrates that comple-
ment classical, alternative and terminal pathways are ac-
tivated and we show for the first time that complement
expression is notable in and on large neurons in MS cor-
tical grey matter lesions. Our data suggest that a dysreg-
ulation of complement activation and control occurs in
the MS brain, and an increase in complement anaphyla-
toxin receptor-positive microglia may serve to sustain
the neuroinflammatory response that drives myelin and
neuronal pathology in the progressive phase.
Complement is activated in MS cortical grey matter lesions
In the cortical grey matter, C1q expression was seen in
and on neurons, neurites and glia. The pattern of stain-
ing suggested biosynthesis as well as a deposition of
complement, which is supported by C1q mRNA expres-
sion in NeuN+ neurons, shown here and by others [22].
Evidence for alternative complement pathway activation
in our study is seen in the elevated number of activation
fragment Bb+ cells. Therefore, localisation of the opso-
nin C3b (and its breakdown product iC3b) in and on
neurons in GMLs of the cortex, thalamus and hippo-
campus may be a consequence of classical and/or alter-
native pathway activation.
Proteolysis of C3 yields C3a, a soluble anaphylatoxin
that activates both protective and damaging immune re-
sponses against neurons through C3aR engagement.
Membrane bound C3b activates CR3+ microglia to trig-
ger activation that can be detrimental to cell integrity,
whilst recent evidence suggests that C3a and C3b can be
generated intracellularly [31]. Accumulation of C3b can
lead to formation of the C5 convertase and release of
C5a, which is damaging to neurons via C5aR activation
[32, 33]. We show that the number of C5aR+ microglia
is increased in chronic cortical lesions. C5b formation
and the subsequent recruitment of C6-9 lead to the for-
mation of MAC. MAC deposition is seen in acute and
chronic MS WMLs [19, 34, 35] but hitherto has not
been demonstrated for cortical GMLs. The MAC may
be directly cytopathic (there is a significant loss of cor-
tical neurons in these same lesions of interest, Fig. 5),
but even sublethal attack can trigger the production of
pro-inflammatory cytokines and reactive oxygen species,
stimulate binding of damage-associated molecular pat-
terns [36], confer protection [37] or mediate NLRP3
inflammasome-induced IL1β synthesis [38].
Our quantitative findings are in agreement with quali-
tative reports describing C1q, C3d and C4d immunore-
activity in some cortical GMLs [18–21], and quantitative
measures of elevated C1q and C3d labelling in the
hippocampus [22], in a cell-associated pattern of immu-
nostaining similar to that seen by us in the cortical grey
matter. In agreement with previous publications [18, 19],
we noted that the pattern of complement immunoreac-
tivity (recognition molecules and activation fragments)
was most striking in cortical layers V–VI near the white
matter border; however, we report that the density of
complement-labelled cells was not related to the pres-
ence of underlying WMLs (Additional file 1: Figure S5),
confirming that a major part of the complement re-
sponse is generated locally by cells of the cortical grey
matter.
Complement regulator expression in MS cortical grey
matter lesions does not increase with activation—evidence
for dysregulation?
Uncontrolled activation of complement is detrimental to
the host and results in progressive cell and tissue injury
in the chronically inflamed organ [13]. Each complement
activation pathway is regulated at multiple strategic
points to prevent uncontrolled activation. We did not
detect a significant difference in the numerical density of
cells immunolabelled for C1INH or FH between MS
cortical grey matter and control samples. The demon-
stration of unchanged number of complement regulator-
positive cells despite on-going complement activation
suggests that the drive to complement activation over-
whelms regulation. We suggest that such a disparity be-
tween markers of activation and regulation of the
classical and alternative complement pathways manifests
as the robust and widespread expression of fragments of
complement activation, leading to the unchecked gener-
ation of opsonin and soluble anaphylatoxin products
that may exacerbate the pathology in the progressive MS
brain. It is for these reasons that complement markers
could be valuable prognostic indicators of a more severe
disease [15, 17].
Microglial activation and neuronal injury and loss
We are interested in the pathomechanisms of cortical
and neuronal injury due to their relevance to disability
progression in MS [1]. There was significant loss of neu-
rons from the deep cortical laminae that corresponded
to the areas of elevated numbers of complement-labelled
cells and a greater proportion of large neurons co-
labelled with C3b. Loss of cortical neurons will be a con-
sequence of numerous factors, including demyelination,
cytokine or cell-mediated cytotoxicity, de-innervation,
retrograde degeneration, mitochondrial dysfunction and
excitotoxicity (reviewed by [39]), to which biosynthesis
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and deposition of products of complement activation, in
the presence of increased numbers of complement re-
ceptor positive microglia, could be contributory. These
findings suggest that in this environment of significant
neuronal loss, a substantial proportion of the remaining
large (Smi32+) neurons are under inflammatory stress
and appear dysmorphic, which would render them dys-
functional. Complement may drive neuronal damage
through C3b(iC3b)-CR3 activation of phagocytes in a
process of primary phagocytic damage [40] or through
the activation of local glia through anaphylatoxin recep-
tor engagement that can cause dendritic damage and
neuronal toxicity [10, 41, 42]. Complement synthesised by
neurons could be a physiological response to stress, which
may aid synaptic pruning by locally activated microglia or
engage neuronal complement receptors resulting in al-
tered neuritic and synaptic presentation [9, 22].
Conclusions
The presence of complement activation products and
anaphylatoxin receptor positive activated microglia sug-
gest that neurons in the MS cortical grey matter are sub-
ject to a sustained innate immune attack that may
contribute to their dysfunction and death. Our work
supports efforts to investigate the utility of complement
as a potential biomarker or therapeutic target for pro-
gressive MS.
Additional file
Additional file 1: Table S1. Demographic and pathological details for
cases used in this study. All cases were retrospectively confirmed as MS,
non-inflammatory or inflammatory (viral encephalitis or ischaemia) following
detailed analysis of patient health records and full neuropathological work
up. Region matched sections (FFPE or cryosections) were available for all
cases from the frontal cortex (sup. Frontal gyrus), cingulate cortex and
hippocampus and temporal (inf.) gyrus. Tissue sections from inflammatory
control cases were selected based on region-matching and not on the
presence of pathology in the particular block. Examples of myelin and
inflammatory cell staining are shown in Additional file: Figure S1.
Abbreviations: PMD- post-mortem delay from death to tissue processing
(hrs); Disease activity- neuropathologically defined disease activity based on
the presence (Active) or absence (Stable) of active inflammatory lesions;
Disease duration is calculated from retrospectively determined time of dis-
ease onset; Tissue- available formalin-fixed paraffin embedded (FFPE) or
cryopreserved tissue blocks; Quantified lesions- number of GM or WM lesion
regions of interest analysed in this quantitative study. Table S2. Primary
antibodies used in this study, retrieval conditions and commercial source.
Citrate- 100mM sodium citrate, 10mM citric acid, pH 6.0; TRIS/ EDTA- 10mM
Tris, 1mM EDTA, pH 8.5. Table S3. Complement cell-associated expression
was not related to age of death, post-mortem delay or whether death was
infection (inflammatory) or non-infection related. Linear regression and
Pearson’s correlation analysis (Age of death and PMD (post mortem delay)
versus mean C3b+ cell count per case) or Mann-Whitney test of mean C3b
+ cell count between those cases with an inflammatory-related or non-
inflammatory disease noted at death. Figure S1. Non-neurological controls
and inflammatory neurological controls used in this study. Control cortical
grey and subcortical white matter was characterised by a uniform pattern of
anti-MOG staining (A- D) and small numbers of ramified HLA-D+ microglia
(E- H). Inflammatory controls were selected on the basis of available region-
matched blocks and frequently displayed an unremarkable pathology.
Occasional areas of microglial activation were noted in some sections of
cortical and subcortical tissue (I- P; ischaemic encephalitis inflammatory
control), whilst perivascular cuffs of activated microglia and macrophages
were sometimes seen in cases of viral encephalitis (Q- X). Scale bars= W
(and all low power images) 100µm; X (and all high power images) 20µm.
Figure S2. Complement recognition fragment, activation products and
regulator expression in MS, non-MS inflammatory controls (IC) and non-
neurological control (Ctrl) grey matter. 400x magnification images of C1q
(A-C), C1-inhibitor (D-F), Bb (G-I), factor H (J-L), C3b-iC3b (M-O), MAC (P, Q)
and clusterin (R, S) in deeper cortical laminae of control (Ctrl; left column &
P, R), MS (central column & Q, S) and non-MS inflammatory controls (right
column only) showing the cell-specific and often robust pattern of anti-
complement immunostaining seen in MS (and to a lesser extent, non-MS
inflammatory controls) cortical grey matter in comparison to non-diseased
controls. Scale bar= 20µm. Figure S3. Complement recognition fragment,
activation product and regulator expression in subcortical white matter
samples. 400x magnification images of C1q (A-C), C1-inhibitor (D-F), Bb (G-I),
factor H (J-L), C3b-iC3b (M-O), MAC (P, Q) and clusterin (R, S) in sub-cortical
white matter of non-neurological control (Ctrl), MS and non-MS
inflammatory controls (IC), showing the cell-specific and often robust
pattern of anti-complement immunostaining seen in MS white matter in
comparison to non-neurological controls. Scale bar= 20µm. Figure S4.
Examples of complement immunolabelling in Alzheimer’s disease (AD).
Two AD cases (age of death, 85 and 96yrs; gender, both female; post-
mortem delay, 30 and 19hrs, respectively), showed complement specific
immunolabelling with anti-C1q, C3b-iC3b and C9neo of cells resembling
neurons and glia (similar to that seen in MS and controls), as well as
diffuse labelling of amyloid plaques (for anti-C1q, C3b and C9neo
antibodies). Cellular immunolabelling of C1INH and clusterin resembles
that seen in control, MS and inflammatory control cases. C5aR+ glia
were also seen in the AD deep grey matter. All images captured at 200x
magnification. Figure S5. Complement activation in cortical grey matter
is not related to underlying white matter inflammation. Grey matter lesions
of the deeper cortical laminae are characterised as type I (involving both
the white and grey matter) or type IV (involving the entire vertical extent of
the cortex but without affecting the underlying white matter). Our analysis
revealed there to be no difference between the density of C1q (A,B and D)
and C3b-labelled cells (C) in type I grey matter lesions (that are associated
with white matter lesions) and type IV lesions. Scatter graphs of type I versus
type IV cell-specific counts for C1q and C3b quantitative immunostaining
compared by Mann-Whitney test. (PDF 1849 kb)
Abbreviations
C1INH, C1 inhibitor; Clu, clusterin; Creg, complement regulator; Ctrl, control
cohort; FH, factor H; GML, grey matter lesion; GMN, normal appearing grey
matter; IC, non-MS inflammatory controls; MAC, membrane attack complex;
MOG, myelin-oligodendrocyte glycoprotein; WML, white matter lesion
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